Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: A prospective observational study

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 4, 2003, Pages 581-586

  Karasek, Petr ^a   Skacel, Tomas ^b   Kocakova, Ilona ^a   Bednarik, Otakar ^a   Petruzelka, Lubos ^c   Melichar, Bohuslav ^d   Bustova, Ivana ^e   Spurny, Vladimir ^f   Trason, Tomas ^b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b Medicoop Kromeriz   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^e Hospital Ceske Budejovice   (Czech Republic)

^f ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Gemcitabine; Monotherapy; Observational study; Pancreatic cancer

Indexed keywords

ANALGESIC AGENT; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MORPHINE SULFATE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RUBITECAN; TIPIFARNIB; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PROGNOSIS; PROSPECTIVE STUDY; THROMBOCYTOPENIA;

EID: 0242585483     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.4.581     Document Type: Article

References (28)

1. Neoplasms 1998 - Cancer Incidence 1998 in the Czech Republic. Institute of Health Information and Statistics of the Czech Republic (Ustav zdravotnickych informaci a statistiky Ceske republiky). Prague (2001):58.
2. BRAMHALL SR, ROSEMURGY A, BROWN PD, BOWRY C, BUCKELS JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. (2001) 19:3447-3455.
3. HALL PA, LEMOINE NR: Models of pancreatic cancer. Cancer Surv. (1993) 16:135-155.
4. HAHN SA, SCHMIEGEL WH: Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion (1998) 59:493-501.
5. YEO CJ, CAMERON JL, LILLEMOE KD et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann. Surg. (1995) 221:721-733.
6. DECAPRIO JA, MAYER RJ, GONIN R, ARBUCK SG: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a Phase II trial. J. Clin. Oncol. (1991) 9:2128-2133.
7. GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet (2001) 357:1478-1484.
8. VON DER MAASE H, ANDERSEN L, CRINO L, WEINKNECHT S, DOGLIOTTI L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann. Oncol. (1999) 10:1461-1465.
9. ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. (1996) 7:347-353.
10. CARMICHAEL J, FINK U, RUSSELL RC et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1996) 73:101-105.
11. STORNIOLO AM, ENAS NH, BROWN CA, VOI M, ROTHENBERG ML, SCHILSKY R: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer (1999) 85:1261-1268.
12. BURRIS HA, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
13. ANDERSEN JS, BURRIS HA, CASPER E et al.: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proceedings of the 30th Annual Meeting for the American Society of Clinical Oncology, Dallas, USA (1994):A1600.
14. KLEIN B, SADIKOV E, MISHAELI M, LEVIN I, FIGER A: Comparison of 5-FU and leucovotin to gemcitabine in the treatment of pancreatic cancer. Oncol. Rep. (2000) 7:875-877.
15. BRAMHALL SR, ALLUM WH, JONES AG, ALLWOOD A, CUMMINS C, NEOPTOLEMOS JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. (1995) 82:111-115.
16. KARASEK P, NENUTIL R, VOJTESEK B, VYZULA R: The response of advanced pancreatic cancer (APC) to gemcitabine monochemotherapy in relation to the expression of proliferation markers, oncogenes Her-2, Bcl-2, C-myc and p53 antioncogene. A retrospective clinico-pathological study. Proceedings of the 11th European Cancer Conference, Lisbon, Portugal (2001):S120.
17. VAN CUTSEM E, KARASEK P, OETTLE H et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proceedings of the 38th Annual Meeting for the American Society of Clinical Oncology, Orlando, USA (2002):130a.
18. ROWINSKY EK, WINDLE JJ, VON HOFF DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. (1999) 17:3631-3652.
19. KIMURA W, ZHAO B, FUTAKAWA N, MUTO T, MAKUUCHI M: Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas. Hepatogastroenterology (1999) 46:532-539.
20. HEINEMANN V, WILKE H, MERGENTHALER HG et al.: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol. (2000) 11:1399-1403.
21. COLUCCI G, RICCARDI F, GIULIANI F et al.: Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): a Phase II multicenter study of the Southern Italy Oncology Group. Proceedings of the 35th Annual Meeting for the American Society of Clinical Oncology, Atlanta, USA (1999):250a.
22. LOUVET C, HAMMEL R ANDRE T et al.: Multicenter Phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM Regimen). Proceedings of the 35th Annual Meeting for the American Society of Clinical Oncology, Atlanta, USA (1999):275a.
23. MOUSSEAU M, REBISCHUNG C, GARNIER C et al.: Phase I/II study in advanced pancreatic adenocarcinoma (APA) and carcinoma of unknown primary (CUP): a combination of leucovorin (LV), 5-FU bolus and infusion, gemcitabine (GEM) and oxaliplatin (LOHP) (FOLFU GEMOX regimen). Proceedings of the 36th Annual Meeting for the American Society of Clinical Oncology New Orleans, USA (2000):233a.
24. CASCINU S, SILVA RR, BARNI S et al.: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian group for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer (1999) 80:1595-1598.
25. CLARK JW, RYAN DP, KULKE MH et al.: Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic cancer. Proceedings of the 36th Annual Meeting for the American Society of Clinical Ontology, New Orleans, USA (2000):313a.
26. ABBRUZZESE JL, ROSENBERG A, XIONG Q et al.: Phase II Study of antiepidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proceedings of the 37th A nnual Meeting for the American Society of Clinical Oncology San Francisco, USA (2001):130a.
27. SAFRAN H, RAMANATHAN RK, SCHWARTZ J et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proceedings of the 37th Annual Meeting for the American Society of Clinical Oncology San Francisco, USA (2001):130a.
28. BOLD RJ, CHANDRA J, MCCONKEY DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. (1999) 6(3):279-285.